CLINICAL TRIALS PROFILE FOR GLIPIZIDE; METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for GLIPIZIDE; METFORMIN HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00513630 ↗ | Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease | Completed | Shanghai Jiao Tong University School of Medicine | Phase 4 | 2004-06-01 | The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation |
NCT00648505 ↗ | Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fed conditions. |
NCT00649454 ↗ | Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-06-01 | The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting conditions. |
NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | Bristol-Myers Squibb | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | AstraZeneca | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLIPIZIDE; METFORMIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for GLIPIZIDE; METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for GLIPIZIDE; METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for GLIPIZIDE; METFORMIN HYDROCHLORIDE
Sponsor Name